386 related articles for article (PubMed ID: 31783119)
1. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
[TBL] [Abstract][Full Text] [Related]
3. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
4. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
Li YX; Sibon OCM; Dijkers PF
J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
[TBL] [Abstract][Full Text] [Related]
7. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
8. RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context.
Jazurek-Ciesiolka M; Ciesiolka A; Komur AA; Urbanek-Trzeciak MO; Krzyzosiak WJ; Fiszer A
J Mol Biol; 2020 Dec; 432(24):166699. PubMed ID: 33157084
[TBL] [Abstract][Full Text] [Related]
9. Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV
J Neurol Sci; 2023 Nov; 454():120828. PubMed ID: 37865002
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
Krauss S; Nalavade R; Weber S; Carter K; Evert BO
Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
[TBL] [Abstract][Full Text] [Related]
11. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.
Prudencio M; Garcia-Moreno H; Jansen-West KR; Al-Shaikh RH; Gendron TF; Heckman MG; Spiegel MR; Carlomagno Y; Daughrity LM; Song Y; Dunmore JA; Byron N; Oskarsson B; Nicholson KA; Staff NP; Gorcenco S; Puschmann A; Lemos J; Januário C; LeDoux MS; Friedman JH; Polke J; Labrum R; Shakkottai V; McLoughlin HS; Paulson HL; Konno T; Onodera O; Ikeuchi T; Tada M; Kakita A; Fryer JD; Karremo C; Gomes I; Caviness JN; Pittelkow MR; Aasly J; Pfeiffer RF; Veerappan V; Eggenberger ER; Freeman WD; Huang JF; Uitti RJ; Wierenga KJ; Marin Collazo IV; Tipton PW; van Gerpen JA; van Blitterswijk M; Bu G; Wszolek ZK; Giunti P; Petrucelli L
Sci Transl Med; 2020 Oct; 12(566):. PubMed ID: 33087504
[TBL] [Abstract][Full Text] [Related]
12. Toward understanding Machado-Joseph disease.
Costa Mdo C; Paulson HL
Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
[TBL] [Abstract][Full Text] [Related]
13. Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis.
Chakraborty A; Tapryal N; Venkova T; Mitra J; Vasquez V; Sarker AH; Duarte-Silva S; Huai W; Ashizawa T; Ghosh G; Maciel P; Sarkar PS; Hegde ML; Chen X; Hazra TK
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8154-8165. PubMed ID: 32205441
[TBL] [Abstract][Full Text] [Related]
14. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
[TBL] [Abstract][Full Text] [Related]
15. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.
Watanave M; Hoshino C; Konno A; Fukuzaki Y; Matsuzaki Y; Ishitani T; Hirai H
Neurobiol Dis; 2019 Jan; 121():263-273. PubMed ID: 30343032
[TBL] [Abstract][Full Text] [Related]
17. Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease.
Raposo M; Hübener-Schmid J; Tagett R; Ferreira AF; Vieira Melo AR; Vasconcelos J; Pires P; Kay T; Garcia-Moreno H; Giunti P; Santana MM; Pereira de Almeida L; Infante J; van de Warrenburg BP; de Vries JJ; Faber J; Klockgether T; Casadei N; Admard J; Schöls L; Riess O; ; Costa MDC; Lima M
Neurobiol Dis; 2024 Apr; 193():106456. PubMed ID: 38423193
[TBL] [Abstract][Full Text] [Related]
18. FipoQ/FBXO33, a Cullin-1-based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein.
Chen ZS; Wong AKY; Cheng TC; Koon AC; Chan HYE
J Neurochem; 2019 Jun; 149(6):781-798. PubMed ID: 30685895
[TBL] [Abstract][Full Text] [Related]
19. Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem Cells.
Ou Z; Luo M; Niu X; Chen Y; Xie Y; He W; Song B; Xian Y; Fan D; OuYang S; Sun X
Biomed Res Int; 2016; 2016():6701793. PubMed ID: 27847820
[TBL] [Abstract][Full Text] [Related]
20. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3.
Koike Y; Jansen-West KR; Hanna Al-Shaikh R; Carlomagno Y; Song Y; Dunmore JA; LeDoux MS; Friedman JH; Pena AB; Uitti RJ; Zaremba J; van Gerpen JA; Pfeiffer RF; Veerappan V; Aiba I; Hashimoto R; Giles SS; Shah JS; Tipton PW; Huang JF; Wierenga KJ; Aasly J; Fryer JD; Petrucelli L; Wszolek ZK; Prudencio M
Parkinsonism Relat Disord; 2021 Aug; 89():151-154. PubMed ID: 34303201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
